IP Library Granted Patent US 11,060,067
Granted Patent B2
US 11,060,067 · App. 15/515,837 · Granted Jul 13, 2021

Human liver microphysiology platform and self assembly liver acinus model and methods of their use

Inventors: D. Lansing Taylor (Pittsburgh, PA); Albert Gough (Glenshaw, PA); Larry Vernetti (Wexford, PA)
C12N5/0697B01L3/502715B01L3/502761C12M23/16C12M35/08C12N5/067G01N33/5067G01N33/5082B01L2300/0636C12N2502/11C12N2502/14C12N2502/28C12N2510/00C12N2513/00C12N2533/50C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,060,067
App. No.
15/515,837
Granted
Jul 13, 2021
Kind
B2
Abstract

Microfluidic devices for modeling three-dimensional tissue structures and methods for making and using the same are described herein.

Claims (39)

1. A microfluidic device comprising:

a housing having at least one inlet and at least one outlet;

extracellular matrix proteins disposed on at least one surface of the housing;

parenchymal hepatic cells dispersed in self-assembled cord formations on the extracellular matrix proteins;

cells of at least two types comprising endothelial cells and immune cells,

wherein the parenchymal hepatic cells together with cells of at least two types associated with the extracellular matrix proteins and form three-dimensional structures within the housing; and

a flow medium contacting the parenchymal hepatic cells and endothelial and immune cells, wherein the three-dimensional structures are liver acini.

2. The device of claim 1 , wherein the parenchymal hepatic cells comprise one or more of cultured hepatocytes, hepatocytes derived from induced pluripotent stem cells, and primary hepatocytes, endothelial cells, immune cells, stellate cells, and combinations thereof.

3. The device of claim 1 , further comprising genetically modified cells expressing a genetically encoded fluorescence based biosensors.

4. The device of claim 3 , wherein expression of the genetically encoded fluorescence based biosensor is dependent upon calcium levels, pH, glutathione levels, mitochondrial calcium levels, oxidative stress, or reactive oxygen species.

5. The device of claim 3 , wherein expression of the genetically encoded fluorescence based biosensor is in response to apoptosis, change in mitochondrial membrane potential, cell proliferation, free calcium ion concentration, cell motility, and oxidative stress response.

6. The device of claim 1 , wherein the one or more three-dimensional structures have established zonation.

7. The device of claim 1 , further comprising a pump fluidly connected to the inlet configured to propel flow medium through the housing.

8. The device of claim 1 , wherein the housing comprises one or more chambers and one or more passages fluidly connecting the chambers.

9. The device of claim 8 , wherein the extracellular matrix proteins are disposed in the chambers of the housing.

10. The device of claim 1 , further comprising a sensor positioned to detect analytes in effluent exiting the housing.

11. The device of claim 1 , further comprising an imager positioned to image the three-dimensional structures.

12. The device of claim 1 , further comprising one or more ports positioned to introduce substances into the flow medium.

13. The device of claim 1 , wherein the endothelial cells are EAhy.926 endothelial cells and the immune cells are U937 monocytic cells.

14. The device of claim 1 , where the endothelial cells and immune cells are dispersed between the cord formations.

15. The device of claim 1 , wherein the three dimensional structures are self-assembled.

16. The device of claim 1 , further comprising polymerized collagen.

17. The device of claim 1 , further comprising stellate cells.

18. The device of claim 1 , wherein the stellate cells are LX-2 stellate cells.

19. The device of claim 1 , wherein the liver acini are capable of producing bile.

20. A method for self-assembly of three-dimensional structures of liver acini comprising:

providing a surface coated with an extracellular matrix protein;

contacting the surface with parenchymal hepatic cells to form self-assembled cord formations on the extracellular matrix proteins;

incubating the parenchymal hepatic cells for about 12 to about 16 hours in a flow medium;

contacting the surface with endothelial cells and immune cells;

incubating the parenchymal hepatic cells and endothelial and immune cells for about 1 to about 12 hours in a flow medium thereby forming three-dimensional structures of liver ancini; and

contacting the surface with polymerized collagen.

21. The method of claim 20 , wherein the surface is disposed within a microfluidic device.

22. The method of claim 20 , wherein contacting the surface with polymerized collagen comprises:

introducing collagen into the microfluidic device;

inverting the microfluidic device;

polymerizing the collagen; and

inverting the microfluidic device.

23. The method of claim 20 , wherein the parenchymal hepatic cells are genetically modified to express a genetically encoded fluorescence-based biosensor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: NORTIS, INC.
To: QURIS TECHNOLOGIES LTD.
Reel/Frame 068618/0221 →
LICENSE Recorded Aug 26, 2024
From: UNIVERSITY OF PITTSBURGH
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068789/0551 →
Continuity (2)
Provisional Application 62057625 · Sep 30, 2014
Related Publication 20170292117A1 · Oct 12, 2017